Relationship between bacille calmette-guerin (bcg) strains and the efficacy of bcg vaccine in the prevention of tuberculosis

Timothy F. Brewer; Graham A. Colditz

doi:10.1093/clinids/20.1.126

Relationship between bacille calmette-guerin (bcg) strains and the efficacy of bcg vaccine in the prevention of tuberculosis

Timothy F. Brewer, Graham A. Colditz

Research output: Contribution to journal › Article › peer-review

93 Scopus citations

Abstract

Bacille Calmette-Guerin (BCG) vaccination for the prevention of tuberculosis has been used in humans since 1921. Furthermore, for >60 years it has been possible to separate BCG strains (defined here as a BCG vaccine maintained in a particular laboratory and used in a particulartrial or set of trials) on the basis of in vitro and in vivo tests. Investigators have concluded that differences in the BCG strains used in efficacy trials on humans may be responsible forthe widerange in levels of protection from tuberculosis reported in those trials. We review the development of the separate strains used in the trials included in a recent meta-analysis and examine data for and against the protective efficacy of different BCG strains. The difficulties incorrelating results of in vitro and in vivo tests with protective efficacy in humans are discussed. Thelimited data available from human studiessuggest that the BCG strain used for vaccinationis not a significant determinant of the overall efficacy in the prevention of tuberculosis.

Original language	English
Pages (from-to)	126-135
Number of pages	10
Journal	Clinical Infectious Diseases
Volume	20
Issue number	1
DOIs	https://doi.org/10.1093/clinids/20.1.126
State	Published - Jan 1995

Access to Document

10.1093/clinids/20.1.126

Cite this

@article{5d1943f716bf4f9bbe3c546099a341c5,

title = "Relationship between bacille calmette-guerin (bcg) strains and the efficacy of bcg vaccine in the prevention of tuberculosis",

abstract = "Bacille Calmette-Guerin (BCG) vaccination for the prevention of tuberculosis has been used in humans since 1921. Furthermore, for >60 years it has been possible to separate BCG strains (defined here as a BCG vaccine maintained in a particular laboratory and used in a particulartrial or set of trials) on the basis of in vitro and in vivo tests. Investigators have concluded that differences in the BCG strains used in efficacy trials on humans may be responsible forthe widerange in levels of protection from tuberculosis reported in those trials. We review the development of the separate strains used in the trials included in a recent meta-analysis and examine data for and against the protective efficacy of different BCG strains. The difficulties incorrelating results of in vitro and in vivo tests with protective efficacy in humans are discussed. Thelimited data available from human studiessuggest that the BCG strain used for vaccinationis not a significant determinant of the overall efficacy in the prevention of tuberculosis.",

author = "Brewer, {Timothy F.} and Colditz, {Graham A.}",

note = "Funding Information: Received 13 December 1993; revised 14 July 1994. Financial support: This work was supported by the Centers for Disease Control and Prevention through a collaborative agreement with the Association for Schools of Public Health. T.F.B. was supported by an Alfred L. Frechette Postdoctoral Research Fellowship in Public Health from the Massachusetts Health Research Institute, Boston, and a grant from the Potts Memorial Foundation, Hudson, New York. Reprints or correspondence: Dr. Timothy F. Brewer, Channing Laboratory, 180 Longwood Avenue, Boston, Massachusetts 02115.",

year = "1995",

month = jan,

doi = "10.1093/clinids/20.1.126",

language = "English",

volume = "20",

pages = "126--135",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

number = "1",

}

TY - JOUR

T1 - Relationship between bacille calmette-guerin (bcg) strains and the efficacy of bcg vaccine in the prevention of tuberculosis

AU - Brewer, Timothy F.

AU - Colditz, Graham A.

N1 - Funding Information: Received 13 December 1993; revised 14 July 1994. Financial support: This work was supported by the Centers for Disease Control and Prevention through a collaborative agreement with the Association for Schools of Public Health. T.F.B. was supported by an Alfred L. Frechette Postdoctoral Research Fellowship in Public Health from the Massachusetts Health Research Institute, Boston, and a grant from the Potts Memorial Foundation, Hudson, New York. Reprints or correspondence: Dr. Timothy F. Brewer, Channing Laboratory, 180 Longwood Avenue, Boston, Massachusetts 02115.

PY - 1995/1

Y1 - 1995/1

N2 - Bacille Calmette-Guerin (BCG) vaccination for the prevention of tuberculosis has been used in humans since 1921. Furthermore, for >60 years it has been possible to separate BCG strains (defined here as a BCG vaccine maintained in a particular laboratory and used in a particulartrial or set of trials) on the basis of in vitro and in vivo tests. Investigators have concluded that differences in the BCG strains used in efficacy trials on humans may be responsible forthe widerange in levels of protection from tuberculosis reported in those trials. We review the development of the separate strains used in the trials included in a recent meta-analysis and examine data for and against the protective efficacy of different BCG strains. The difficulties incorrelating results of in vitro and in vivo tests with protective efficacy in humans are discussed. Thelimited data available from human studiessuggest that the BCG strain used for vaccinationis not a significant determinant of the overall efficacy in the prevention of tuberculosis.

AB - Bacille Calmette-Guerin (BCG) vaccination for the prevention of tuberculosis has been used in humans since 1921. Furthermore, for >60 years it has been possible to separate BCG strains (defined here as a BCG vaccine maintained in a particular laboratory and used in a particulartrial or set of trials) on the basis of in vitro and in vivo tests. Investigators have concluded that differences in the BCG strains used in efficacy trials on humans may be responsible forthe widerange in levels of protection from tuberculosis reported in those trials. We review the development of the separate strains used in the trials included in a recent meta-analysis and examine data for and against the protective efficacy of different BCG strains. The difficulties incorrelating results of in vitro and in vivo tests with protective efficacy in humans are discussed. Thelimited data available from human studiessuggest that the BCG strain used for vaccinationis not a significant determinant of the overall efficacy in the prevention of tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=0028851078&partnerID=8YFLogxK

U2 - 10.1093/clinids/20.1.126

DO - 10.1093/clinids/20.1.126

M3 - Article

C2 - 7727638

AN - SCOPUS:0028851078

SN - 1058-4838

VL - 20

SP - 126

EP - 135

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 1

ER -

Relationship between bacille calmette-guerin (bcg) strains and the efficacy of bcg vaccine in the prevention of tuberculosis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this